Chris Viehbacher, Biogen CEO (Photographer: Scott Eells/Bloomberg via Getty Images)

April 25, 2023 07:29 AM EDTUpdated 01:18 PM

Updated: Biogen chops certain stroke and RNA therapy programs as it continues R&D revamp

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

Biogen plans to scrap three clinical programs and “deprioritize” preclinical gene therapy and ophthalmology programs as part of CEO Chris Viehbacher’s larger strategy to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Biogen chops certain stroke and RNA therapy programs as it continues R&D revamp

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Up­dat­ed: Bio­gen chops cer­tain stroke and RNA ther­a­py pro­grams as it con­tin­ues R&D re­vamp

Senior Reporter

News Reporter

Sign up to read this article for free.

Updated: Biogen chops certain stroke and RNA therapy programs as it continues R&D revamp